Health-related quality of life (HRQoL) is the impact a person's health status has on their quality of life. This complex concept encompasses measures across multiple domains of their life, including physical, functional, social, and emotional well-being. As technological advances in oncology occur, maintaining quality of life while improving survival becomes increasingly important. These dual obligations are clearly expressed in the mission statement of the Society of Surgical Oncology to ''improve the practice environment in which high-quality surgical oncology care is delivered, to enhance the quality of life and survival of the surgical patient with cancer.'' 1 In their study, Moaven and colleagues admirably meet this challenge by studying HRQoL using patient-reported outcome measures (PROMs) in patients with mucinous appendiceal cancer undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) as part of a randomized trial comparing two agents, mitomycin and oxaliplatin. 2 It is important to highlight, as discussed by Moaven et al., that the paucity of literature with regard to optimal perfusion agent in appendix cancer has been multifactorial in etiology. 2 Extrapolation in this context from the colorectal cancer literature is not necessarily reflective of the true biology of appendiceal cancer, given it is a separate clinical entity. The authors found that HIPEC perfusion using oxaliplatin resulted in significantly better physical and functional well-being outcomes compared with mitomycin. Given that they also found no significant differences in survival or complication rates between the agents, they make a compelling case that oxaliplatin should be the perfusion agent of choice for patients with mucinous appendiceal cancer undergoing CRS/HIPEC. Moaven et al. 2 comment that the differences in QoL measures between the mitomycin and oxaliplatin arms ''are diminished and clinically insignificant 1 year after surgery.'' However, the first year postoperatively is precisely the time during which patients and families are attempting to recuperate and get back on their feet. The Moaven et al. 2 study showed that ''patients' ability to work were reported to be significantly lower in the mitomycin group at 12 weeks and also 24 weeks after surgery.'' The study also showed that, compared with the patients who received oxaliplatin during HIPEC, the patients who received mitomycin tended to have greater loss of energy, higher pain scores, and greater overall weakness. Cancer patients often struggle with physical and emotional challenges that can derail their ability to tolerate further treatment. In a 2014 study by Marta et al., the majority of patients surveyed wanted treatment options that would prolong life but without compromising their QOL. 3 Other studies have supported the notion that quantity of life is often outweighed by quality-of-life concerns. 4 Patients are hoping to both survive and thrive. If all other factors are equivalent, then it would be desirable to use an intervention that results in a greater quality of life.
One aspect of the study that warrants attention in future studies is the use of the Neurotoxicity (NTX) subscale as the sole symptom subscale. The NTX subscale focuses primarily on symptoms related to peripheral neuropathy commonly observed from systemic use of oxaliplatin. While we acknowledge the importance of ensuring that HIPEC with this agent does not result in significant neurotoxicity, evaluation of the benefits of this intervention on the most common symptoms encountered with this malignancy would also be of interest. As HIPEC is associated with improved survival outcomes in a variety of histologies, developing a subscale specific to this intervention will be an important step.
The neurotoxicity scale (FACT-G/NTX) questionnaire used by Moaven et al. 2 includes helpful sections pertaining to physical well-being, social/family, emotional, and functional effects. However, adverse effects after HIPEC include gastrointestinal complications (anastomotic leak, ileus, delayed gastric emptying) and hematologic complications associated with the chemotherapeutic agents used (including neutropenia). 5 In addition, appendiceal mucinous cancers are often associated with non-specific abdominal symptoms, including pain, distension, and weight loss. 6 Thus, we would recommend that future studies for patients with mucinous appendiceal cancer consider using an additional subscale to assess abdominal symptoms specifically. The FACIT-AI scale is one example. 7 Finally, we would recommend earlier evaluations of QoL postoperatively. The current methods involve assessment of QoL at baseline and at follow-up visits, starting postoperatively at 12 weeks. The authors note that the general QoL score ''decreases at 12 weeks and increases back to baseline afterward.'' 2 Patients often deal with increased pain, constipation, and weakness post-surgery. Accordingly, we would recommend that future studies start postoperative QoL assessments within the first 2 weeks after HIPEC. In our own practice, we have found that an interdisciplinary HIPEC surgical oncology clinic with a team of specialists, including palliative medicine, physical therapy, and registered dieticians, is an effective model of care for patients and their families during the perioperative period. Focusing measures earlier in the perioperative course can help identify timing of appropriate interventions that may further improve the outcomes most meaningful to patients.
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